Conference Coverage

Suzetrigine Use After Surgery Described in US Health Systems

Ashton L. Stahl

Key Highlights

  • The analysis included 3,509 patients who received suzetrigine after a procedure; 84.9% underwent an outpatient procedure.
  • Nearly 30% received suzetrigine as oral monotherapy for acute pain, and 70% received it as part of multimodal analgesia.
  • Median total treatment duration, including refills, was 15 days.

Suzetrigine was used after a range of surgical procedures, primarily in outpatient settings, according to a retrospective analysis of US health system data from its first 9 months after launch. The findings are described in an abstract being presented at the ANESTHESIOLOGY Annual Meeting 2026. 

Researchers used de-identified electronic health records linked to medical and pharmacy claims from the OMNY Health platform for January 31 through October 31, 2025. They included patients aged 17 years or older who had a procedure within 7 days before or on the date of their first documented suzetrigine administration or prescription. Patients also needed at least 3 months of baseline data and 30 days of linked claims follow-up. The analysis described prescribing patterns, treatment duration, refills, and use with opioids, acetaminophen, or nonsteroidal anti-inflammatory drugs (NSAIDs).

Study Findings

The 3,509 patients had a mean age of 62.7 years; 51.4% were aged 65 years or older, and 63.3% were female. Most procedures were outpatient (84.9%). Common procedures included knee arthroplasty in both settings; sleeve gastrectomy among inpatient procedures; and joint arthroscopy and Mohs surgery among outpatient procedures.

The median days’ supply for the initial suzetrigine prescription was 14.5 days, and the median total treatment duration, including refills, was 15 days. Nearly 30% of patients were prescribed or administered suzetrigine as oral monotherapy for acute pain, meaning they had no documented opioids, NSAIDs, or acetaminophen in the hospital and/or outpatient setting. The remaining 70% received it as part of multimodal analgesia.

Of the 530 patients who underwent inpatient procedures, 64.3% received suzetrigine on the day of surgery or on postoperative day 1. Median total treatment duration, including inpatient administration, discharge prescriptions, and refills, was 14 days. Among 2,979 patients who underwent outpatient procedures, 69.5% were prescribed suzetrigine on the day of surgery or postoperative day 1; median total treatment duration, including refills, was 15 days.

Clinical Implications

According to the study authors, these findings offer early insight into how suzetrigine was used across surgical procedures and care settings within US health systems. The authors noted limitations inherent to electronic health record and claims analyses: prescribing and administration records reflect provider intent, while pharmacy claims may not capture every dispensed medication or confirm that a patient took it.

Expert Commentary

“These findings provide early insights into real-world utilization of SUZ across diverse care settings within US health systems,” the researchers concluded.

Reference

Dasa V, Rasouliyan L, Mehta J, Menzie A. Suzetrigine use for postoperative pain: real-world evidence from US health systems. Abstract A2091. Scheduled for presentation at: ANESTHESIOLOGY 2026; October 16-20, 2026; San Diego, CA.